Oral retinoid (Ro 10-9359) in children with lamellar ichthyosis, epidermolytic hyperkeratosis and symmetrical progressive erythrokeratoderma.
8 children with lamellar ichthyosis, 1 with epidermolytic hyperkeratosis and 5 with symmetrical progressive erythrokeratoderma were treated with a new aromatic retinoid (Ro 10-9359). Clinical improvement was dramatic. The children acquired an appearance never obtained before with other managements. The treatment had to be maintained to prevent recurrence. The tolerance to the drug was good. The side-effects were minimal and tended to disappear after several months of treatment. Our results suggest that because of its efficacy, good tolerance and easy administration, the oral retinoid Ro 10-9359 is at present the treatment of choice for the great ichthyotic disorders of children.
D002648:Child; D002675:Child, Preschool; D003873:Dermatitis, Exfoliative / Q000188:drug therapy*; D005050:Etretinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007057:Ichthyosis / Q000188:drug therapy*; D007223:Infant; D007642:Keratosis / Q000188:drug therapy*; D008297:Male; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy*; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate